Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes

Zhang, Rui; Jiao, Qian; Li, Xiaofeng; Yuan, Ye

doi:10.1136/bjophthalmol-2016-310044

Cited by 37 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liposomal drug delivery systems have also been used in other autoimmune diseases. Liposomes were used for infliximab delivery to the eyes in the rat model of experimental autoimmune uveoretinitis [44] and methylprednisolone hemisuccinate in an experimental autoimmune encephalomyelitis (EAE) model of human multiple sclerosis [45]. Furthermore, liposomes displaying a peptide [46], an antibody (e.g., anti-α8 integrin or anti-CD4 antibody) [23, 47], or glutathione [48] have been employed for drug delivery in other autoimmune diseases including EAE, lupus, and other glomerular diseases.…”

Section: Discussionmentioning

confidence: 99%

Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis

Meka

Venkatesha

Moudgil

2018

Journal of Controlled Release

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial tissue of the joints. Inadequately controlled disease may cause severe joint damage and deformity. Currently, the anti-arthritic drugs are given systemically, and therefore, they are widely distributed to other organs that are not the intended therapeutic targets. Accordingly, using a particular dose/regimen of a drug to achieve an effective local concentration of the drug in arthritic joints may lead to expected adverse effects involving other organs. Thus, improved methods of drug delivery are needed for arthritis therapy. One attractive approach is the targeting of a systemically administered drug to the inflamed joints. We describe here a prototypic drug delivery system using a novel peptide ligand denoted as ART-1. We previously reported ART-1 (=ADK) as a peptide that preferentially homes to the inflamed joints of arthritic rats and binds to synovial endothelial cells. We tested the ART-1-coated liposomes encapsulating a fluorescent compound for binding to activated endothelial cells in vitro and homing to arthritic joints in vivo, compared to control liposomes lacking the ART-1 coating. Similar liposomes but encapsulating an immunomodulatory cytokine interleukin-27 (ART-1-IL-27 liposomes) were tested for their anti-arthritic activity compared with control liposomes. ART-1-displaying liposomes showed better binding to endothelial cells as well as in vivo homing to arthritic joints compared to control liposomes. Furthermore, ART-1-IL-27 liposomes, when intravenously injected to arthritic rats after the onset of arthritis, were more effective in suppressing disease progression than control-IL-27 liposomes lacking ART-1 or free IL-27 at an equivalent dose of IL-27. In addition, ART-1-directed liposomal IL-27 had a better safety profile than undirected liposomal IL-27 or free IL-27, thereby offering an improved therapeutic index for IL-27 therapy. These results provide a proof-of concept for the use of a novel joint-homing peptide for targeted delivery of drugs including biologics or small molecule compounds to arthritic joints with enhanced efficacy and reduced systemic exposure. This targeted therapy platform may be suitable for use in RA patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis

Meka

Venkatesha

Moudgil

2018

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…The application of targeted drug delivery is advancing rapidly in the field of autoimmune diseases. Besides its use for arthritis therapy summarized above, liposomal drug delivery has also been used for therapy in animal models of experimental autoimmune uveoretinitis [50], experimental autoimmune encephalomyelitis [51][52][53]; and SLE (or lupus) [24,54]. Besides the use of peptides and folate described above, antibodies (e.g., anti-α8 integrin or anti-CD4 antibody) [24,54] and glutathione [55] have also been employed as ligands for drug delivery in above studies.…”

Section: Discussionmentioning

confidence: 99%

Peptide-targeted Liposomal Delivery of Dexamethasone for Arthritis Therapy

Meka

Venkatesha

Acharya

et al. 2019

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim: Rheumatoid arthritis is an autoimmune disease affecting the joints. Antiarthritic drugs are given systemically, thereby exposing various healthy organs to these drugs, resulting in adverse reactions. Accordingly, there is an urgent need for targeted drug delivery methods for inflamed joints. Materials & methods: We developed a liposomal drug delivery system using a novel peptide ligand (CKPFDRALC) named ART-2, which homes to the inflamed joints when injected intravenously to rats with adjuvant-induced arthritis. Results: The ART-2-coated liposomes encapsulating an antiarthritic drug, dexamethasone (DEX), were more effective in inhibiting arthritis progression than control-DEX liposomes or free DEX, despite a comparable safety profile. Conclusion: Peptide-targeted therapy has advantages over conventional drug delivery and can be adapted for rheumatoid arthritis therapy.

show abstract

“…Los liposomas son ideales porque encapsulan fármacos tanto hidrofílicos como hidrofóbicos y demuestran una muy buena compatibilidad con los tejidos oculares 50,51 . Ejemplo del uso de este tipo de nanopartículas son las nanosuspensiones de prednisolona e infliximab intravítreo con nanotransportador liposomal 52,53 .…”

Section: Liposomasunclassified

Aplicaciones de la nanotecnología en el campo de la oftalmología: ¿dónde estamos?

Gómez-Garzón

Martínez-Ceballos

Gómez-López

et al. 2020

Revista Mexicana De Oftalmología

View full text Add to dashboard Cite

La nanotecnología es una disciplina que se centra en el estudio, procesamiento y aplicación de diversos materiales, aparatos y sistemas funcionales, y controla la materia a nanoescala. La nanomedicina hace referencia a sus aplicaciones para el diagnóstico, tratamiento, prevención y seguimiento de diferentes enfermedades. Los medicamentos que se administran a través de gotas para los ojos deben viajar una gran distancia y evitar varias barreras oculares para llegar al segmento posterior del ojo, lo que lleva a niveles mínimos de medicamento. Esta revisión se centra en los sistemas terapéuticos para enfermedades oculares basados en nanotecnología, y hace énfasis en las barreras que afectan la administración del fármaco ocular y en las enfermedades oculares y los nanosistemas utilizados para su manejo. Se resume la perspectiva de la nanotecnología y los desafíos existentes en la terapia y el diagnóstico de las enfermedades oculares con miras a proporcionar información y nuevas ideas para implementar tratamientos y desarrollar sistemas de manejo de enfermedades oculares intratables.

show abstract

Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes

Cited by 37 publications

References 40 publications

Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis

Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis

Peptide-targeted Liposomal Delivery of Dexamethasone for Arthritis Therapy

Aplicaciones de la nanotecnología en el campo de la oftalmología: ¿dónde estamos?

Contact Info

Product

Resources

About